Perry Nicole D 4
4 · Apellis Pharmaceuticals, Inc. · Filed Mar 3, 2021
Insider Transaction Report
Form 4
Perry Nicole D
Vice President - Finance
Transactions
- Exercise/Conversion
Common Stock
2021-03-01$3.76/sh+2,000$7,520→ 4,347 total - Sale
Common Stock
2021-03-01$50.00/sh−2,000$100,000→ 2,347 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-03-01−2,000→ 11,161 totalExercise: $3.76Exp: 2025-07-31→ Common Stock (2,000 underlying)
Footnotes (2)
- [F1]This is a scheduled exercise from a 10B5-1 trading plan.
- [F2]This option was granted on July 31, 2015 and is fully vested.